Johnson & Johnson announced a proposed settlement valued at an estimated $5.5 billion to resolve approximately 76,000 lawsuits alleging that its talc-based products caused ovarian cancer. The agreement, which still requires approval from 95% of eligible claimants, would resolve nearly all remaining ovarian cancer claims pending in federal and state courts. The company previously settled most asbestos-related mesothelioma claims involving its talc products.
For claims professionals, the settlement represents one of the largest mass tort resolutions in recent years and illustrates how prolonged product liability litigation can evolve through trial verdicts, appeals, expert witness challenges, and settlement negotiations. J&J continues to deny that its talc products caused cancer and maintains the claims lack merit, but said the settlement provides certainty and allows the company to move beyond years of litigation.
The agreement follows a string of courtroom victories for J&J, including favorable trial outcomes, rulings excluding certain plaintiff experts, and a recent federal court decision questioning whether individual plaintiffs could establish that talc specifically caused their ovarian cancer. Those developments likely influenced settlement discussions after the company’s earlier attempts to resolve the litigation through bankruptcy proceedings were rejected by the courts.
Unlike the failed bankruptcy proposals, the new agreement applies only to existing claims and does not include future lawsuits. According to plaintiffs’ attorneys, excluding future claims increases the funds available for current claimants and accelerates payments, with most expected to be completed within 18 months. For insurers, defense counsel, and claims organizations, the settlement highlights the importance of litigation strategy, reserve management, and evaluating the long-term costs of resolving large-scale liability exposures.
